AQ Pharmaceuticals Announces Promising Results for Collagen-GlucoTrojan in Metabolic Health Study

AQ Pharmaceuticals, Inc. (AQP) has announced successful outcomes from a real-world study evaluating JBA Collagen-GlucoTrojan®. Conducted in collaboration with Tastermonial Inc. and led by Dr. Guillermo Repizo and Bude Sethaputra-Piccin, the study explored the supplement's potential benefits for metabolic health. Given the increasing interest in GLP-1 pathways, findings suggest additional research is needed to fully understand its potential.

Collagen-GlucoTrojan® features 250mg of Reducose® and provides a natural solution for blood glucose management without the drawbacks of GLP-1 medications. It aims to inhibit carbohydrate breakdown into glucose, potentially reducing postprandial blood glucose spikes. Notably, the study showed a 26.1% reduction in postprandial glucose levels and suggested benefits for insulin sensitivity and cholesterol ratios.

Participants reported various health improvements, including weight loss, better skin and hair, and joint pain relief. These findings underscore the potential of Collagen-GlucoTrojan® as a natural alternative for metabolic health management. AQP President Tracy Nguyen emphasized the company's commitment to further research to explore these benefits.